newsfilter
← Latest News
Business Wire·

Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

—Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat r